Published Date: 29 Jan 2024
News, features, and analysis on matters pertaining to cancer.
Read Full NewsPrime Minister Keir Starmer said on Wednesday that Britain's biggest company AstraZeneca would invest 300 million pounds ($405 million) in the country, after pausing...
In patients with active RA, switching to upadacitinib after failure of a single TNF inhibitor is more effective in reducing disease activity at 12 weeks than using a second TNF inhibitor adalimumab.
Dr Chu-Yueh Guo discusses promising MS trial results, including a study of fenebrutinib and positive safety data for ocrelizumab in pregnancy and pediatric patients.
Wearables can flag AF and capture symptoms in real time — but who truly benefits? Cardiologist Walid Amara, MD, outlines where smartwatches fit in clinical practice.
Dr Bishal Gyawali unpacks the FDA’s decision to deny RP-1 in melanoma, exploring why single-arm data and confounded response rates failed to meet the bar for clinical evidence.
Experts review the differential diagnosis of suspected IPF, highlighting how a multidisciplinary approach confirmed the diagnosis and informed selection of optimal antifibrotic therapy.
Sypres.io continuously tracks and evaluates psychedelic research, offering an up-to date view of study findings, design, and limitations.
1.
Early-Onset Colorectal Cancer in Male Veterans is Predicted by Risk Factors.
2.
Aspirin for CRC Risk Reduction May Benefit Unhealthy People Most
3.
Since 2000, the outlook for multiple myeloma has improved.
4.
Black women have a higher risk of dying from all types of breast cancer, meta-analysis reveals
5.
We don't all need regular skin cancer screening?but you can know your risk and check yourself
1.
Carboplatin Treatment: What You Need to Know About Side Effects and Efficacy
2.
The Revolutionary Treatment of Hodgkin's Lymphoma: A New Hope for the Future
3.
Unveiling Canine Blood Clots Over Time: A Look at Low-Field MRI's Diagnostic Potential
4.
A New Hope: Exploring the Benefits of Exenteration for Cancer Patients
5.
Bispecific Antibodies in DLBCL & Myeloma: Clinical Insights for Physicians
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
"Lorlatinib Upfront": A Niche but Powerful Option For ALK+ NSCLC
2.
The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
3.
Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL
4.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part IV
5.
Current Scenario of Cancer- An Overview of The Incidence of Cancer in Men
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation